Literature DB >> 15380585

IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk.

Raef S Ahmed1, Robert Y Kim, Jun Duan, Streelatha Meleth, Jennifer F De Los Santos, John B Fiveash.   

Abstract

PURPOSE: To evaluate the feasibility of dose-escalated para-aortic lymph node (PALN) intensity modulated radiation therapy (IMRT) in reducing the dose to bone marrow, bowel, spinal cord, and kidneys, compared with conventional radiation techniques of PALNs in patients with locally advanced cervical cancer and PALN metastases. METHODS AND MATERIALS: Computed tomography scans and MRI studies of 5 cervical cancer patients with PALN involvement were transferred to an IMRT treatment planning workstation (Eclipse/Helios) for image fusion and definition of target volumes and critical structures. The positive PALNs identified on fused computed tomography-magnetic resonance images were defined as the gross target volume (GTV), and the PALN region was defined as the planning target volume. There were 2 distinct treatment regions: the PALN region superior to the isocenter and the whole-pelvis region inferior to the isocenter. Three treatment planning techniques were compared: AP/PA (both regions), 4-field box (both regions), and PALN-IMRT with 4-field box to the whole-pelvis field. With IMRT, the radiation dose to the GTV was escalated from the conventional 45 Gy to 60 Gy (2.4 Gy/fraction), whereas the planning target volume and whole-pelvis region received 45 Gy. The treatment planning isocenter was placed at the L4-L5 vertebral body interspace, and this allowed the two treatment regions to be abutted using independent jaws.
RESULTS: This study has demonstrated the feasibility of escalating the dose delivered to grossly positive PALNs to 60 Gy (2.4 Gy/fraction) with a 95.6% median GTV coverage, concomitantly with conventional treatment of the whole-pelvis region. PALN-IMRT significantly reduced V(40) bone marrow compared to the AP/PA and 4-field box techniques with a median of 21.3%, 98%, and 49.7%, respectively. The PALN-IMRT and 4-field box techniques showed a reduction in V(45) bowel over the AP/PA technique, but a level of statistical significance was not reached. The spinal cord received a significantly higher maximum dose when PALNs were treated with AP/PA fields. Alternatively, the use of the 4-field box technique yielded a significant increase in V(22) kidney on both sides. The placement of the treatment planning isocenter at the L4-L5 interspace allowed the PALN-IMRT and whole-pelvis regions to be treated with a relatively uniform dose at the abutment region.
CONCLUSION: In this dosimetric analysis, we demonstrated that dose-escalated PALN-IMRT with conventional whole-pelvis radiotherapy is feasible with significant sparing of critical normal structures compared to PALN conventional radiation techniques.

Entities:  

Mesh:

Year:  2004        PMID: 15380585     DOI: 10.1016/j.ijrobp.2004.03.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  35 in total

1.  A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer.

Authors:  Wang Jianyang; Tian Yuan; Tang Yuan; Wang Xin; Li Ning; Ren Hua; Fang Hui; Feng Yanru; Wang Shulian; Song Yongwen; Liu Yueping; Wang Weihu; Li Yexiong; Jin Jing
Journal:  Radiol Med       Date:  2015-11-27       Impact factor: 3.469

2.  A novel dynamic field-matching technique for treatment of patients with para-aortic node-positive cervical cancer: Clinical experience.

Authors:  Craig Baden; Alexander Whitley; Javier López-Araujo; Richard Popple; Jun Duan; Robert Kim
Journal:  Rep Pract Oncol Radiother       Date:  2015-11-21

3.  Influence of manipulating hypoxia in solid tumors on the radiation dose-rate effect in vivo, with reference to that in the quiescent cell population.

Authors:  Shin-ichiro Masunaga; Ryoichi Hirayama; Akiko Uzawa; Genro Kashino; Takushi Takata; Hiroki Tanaka; Minoru Suzuki; Yuko Kinashi; Yong Liu; Sachiko Koike; Koichi Ando; Koji Ono
Journal:  Jpn J Radiol       Date:  2010-02-26       Impact factor: 2.374

4.  Magnetic resonance image-guided brachytherapy for cervical cancer : Prognostic factors for survival.

Authors:  Yeon-Joo Kim; Joo-Young Kim; Youngkyong Kim; Young Kyung Lim; Jonghwi Jeong; Chiyoung Jeong; Meyoung Kim; Myong Cheol Lim; Sang-Soo Seo; Sang-Yoon Park
Journal:  Strahlenther Onkol       Date:  2016-10-12       Impact factor: 3.621

5.  Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement.

Authors:  Seok Ho Lee; Seung Heon Lee; Kyu Chan Lee; Kwang Beom Lee; Jin Woo Shin; Chan Yong Park; Sun Jin Sym; Jun-Ho Lee
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

6.  Radiosensitivity of pimonidazole-unlabelled intratumour quiescent cell population to γ-rays, accelerated carbon ion beams and boron neutron capture reaction.

Authors:  S Masunaga; Y Sakurai; H Tanaka; R Hirayama; Y Matsumoto; A Uzawa; M Suzuki; N Kondo; M Narabayashi; A Maruhashi; K Ono
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

7.  Pattern of failure in bladder cancer patients treated with radical cystectomy: rationale for adjuvant radiotherapy.

Authors:  Yong Bae Kim; Sung Joon Hong; Seung Cheol Yang; Jae Ho Cho; Young Deuk Choi; Gwi Eon Kim; Koon Ho Rha; Woong Kyu Han; Nam Hoon Cho; Young Taek Oh
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

8.  Intensity-modulated radiotherapy in patients with cervical cancer. An intra-individual comparison of prone and supine positioning.

Authors:  Carmen Stromberger; Yves Kom; Michael Kawgan-Kagan; Tristan Mensing; Ulrich Jahn; Achim Schneider; Volker Budach; Christhardt Köhler; Simone Marnitz
Journal:  Radiat Oncol       Date:  2010-07-02       Impact factor: 3.481

9.  Extended field intensity-modulated radiotherapy plus concurrent nedaplatin treatment in cervical cancer.

Authors:  Yunqin Liu; Jinming Yu; Liting Qian; Hongyan Zhang; Jun Ma
Journal:  Oncol Lett       Date:  2016-04-06       Impact factor: 2.967

10.  Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomotherapy.

Authors:  Chen-Hsi Hsieh; Ming-Chow Wei; Hsing-Yi Lee; Sheng-Mou Hsiao; Chien-An Chen; Li-Ying Wang; Yen-Ping Hsieh; Tung-Hu Tsai; Yu-Jen Chen; Pei-Wei Shueng
Journal:  Radiat Oncol       Date:  2009-12-10       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.